Biochemotherapeutic strategies and the (dis) utility of hypoxic perfusion of liver, abdomen and pelvis using balloon catheter techniques

European Journal of Surgical Oncology

Volumn 31, Issue 8, 2005, Pages 807-816

  van Ijken, M G A ^a   van Etten, B ^a   Brunstein, F ^a   ten Hagen, T L M ^a   Guetens, G ^b   de Wilt, J H W ^a   de Bruijn, E A ^b   Eggermont, A M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Abdomen; Balloon catheters; Hypoxic perfusion; Liver; Pelvis; Review; Stop flow; TNF

Indexed keywords

MELPHALAN; MITOMYCIN C; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT;

ABDOMEN; ABDOMINAL TUMOR; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BALLOON CATHETER; BLOOD TOXICITY; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE SEVERITY; DRUG DOSE REGIMEN; GASTROINTESTINAL TOXICITY; HUMAN; LIVER BLOOD FLOW; LIVER ISCHEMIA; LIVER PERFUSION; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; MINIMALLY INVASIVE SURGERY; MORBIDITY; MORTALITY; NONHUMAN; PANCREAS CANCER; PELVIS; PELVIS TUMOR; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; TREATMENT CONTRAINDICATION; VALIDATION PROCESS; ANIMAL; BALLOON DILATATION; LIVER TUMOR; METHODOLOGY; REGIONAL PERFUSION;

ABDOMINAL NEOPLASMS; ANIMALS; ANTINEOPLASTIC AGENTS; BALLOON DILATATION; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; LIVER NEOPLASMS; PELVIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 26444465556     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2005.02.032     Document Type: Review

References (88)

1. W.M. Hryniuk A. Figueredo M. Goodyear Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer Semin Oncol 14 4Suppl 4 1987 3-11
2. R.K. Ausman Development of a technic for isolated perfusion of the liver N Y State J Med 61 1961 3993-3997
3. O. Creech Jr E.T. Krementz R.F. Ryan J.N. Winblad Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit Ann Surg 148 4 1958 616-632
4. W.W. Shingleton J.W. Reeves Jr R.A. Keppel S. Mahaley I.M. Taylor Studies on abdominal organ perfusion for cancer chemotherapy Ann Surg 151 1960 741-749
5. A.M. Eggermont H. Schraffordt Koops J.M. Klausner B.B. Kroon P.M. Schlag D. Lienard et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience Ann Surg 224 6 1996 756-764 [discussion 764-5]
6. A.M. Eggermont H. Schraffordt Koops D. Lienard B.B. Kroon A.N. van Geel H.J. Hoekstra et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial J Clin Oncol 14 10 1996 2653-2665
7. L.F. Fajardo H.H. Kwan J. Kowalski S.D. Prionas A.C. Allison Dual role of tumor necrosis factor-alpha in angiogenesis Am J Pathol 140 3 1992 539-544
8. F.J. Lejeune High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: A model for biochemotherapy of cancer Eur J Cancer 31A 6 1995 1009-1016
9. N. Renard D. Lienard L. Lespagnard A. Eggermont R. Heimann F. Lejeune Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha) Int J Cancer 57 5 1994 656-663
10. C. Ruegg A. Yilmaz G. Bieler J. Bamat P. Chaubert F.J. Lejeune Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma Nat Med 4 4 1998 408-414
11. J.H. de Wilt T.L. ten Hagen G. de Boeck S.T. van Tiel E.A. de Bruijn A.M. Eggermont Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion Br J Cancer 82 5 2000 1000-1003
12. B. van Etten M.R. de Vries I.M.G. Van T.E. Lans G. Guetens G. Ambagtsheer et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion Br J Cancer 88 2 2003 314-319
13. A.H. van der Veen J.H. de Wilt A.M. Eggermont S.T. van Tiel A.L. Seynhaeve T.L. ten Hagen TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects Br J Cancer 82 4 2000 973-980
14. D.R. Spriggs M.L. Sherman H. Michie K.A. Arthur K. Imamura D. Wilmore et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study J Natl Cancer Inst 80 13 1988 1039-1044
15. B. Feinberg R. Kurzrock M. Talpaz M. Blick S. Saks J.U. Gutterman A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients J Clin Oncol 6 8 1988 1328-1334
16. D. Lienard P. Ewalenko J.J. Delmotte N. Renard F.J. Lejeune High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma J Clin Oncol 10 1 1992 52-60
17. A.M. Eggermont TNF registered in Europe: Does TNF get a second chance? J Immunother 23 4 2000 505-506
18. M.G. van Ijken B. van Etten J.H. de Wilt S.T. van Tiel T.L. ten Hagen A.M. Eggermont Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model J Immunother 23 4 2000 449-455
19. J.H. de Wilt E.R. Manusama S.T. van Tiel M.G. van Ijken T.L. ten Hagen A.M. Eggermont Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats Br J Cancer 80 1-2 1999 161-166
20. D.L. Bartlett S.K. Libutti W.D. Figg D.L. Fraker H.R. Alexander Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer Surgery 129 2 2001 176-187
21. H.R. Alexander Jr D.L. Bartlett S.K. Libutti D.L. Fraker T. Moser S.A. Rosenberg Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver J Clin Oncol 16 4 1998 1479-1489
22. H.R. Alexander C.K. Brown D.L. Bartlett S.K. Libutti W.D. Figg S. Raje et al. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms Clin Cancer Res 4 10 1998 2357-2362
23. H.R. Alexander S.K. Libutti D.L. Bartlett M. Puhlmann D.L. Fraker L.C. Bachenheimer A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver Clin Cancer Res 6 8 2000 3062-3070
24. P. Lindner M. Fjalling L. Hafstrom H. Kierulff-Nielsen J. Mattsson T. Schersten et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan Eur J Surg Oncol 25 2 1999 179-185
25. M.R. De Vries I.H. Borel Rinkes A.J. Swaak C.E. Hack C.J. Van De Velde T. Wiggers et al. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases Eur J Clin Invest 29 6 1999 553-560
26. T.C. Stam A.J. Swaak M.R. de Vries T.L. ten Hagen A.M. Eggermont Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage Ann Surg Oncol 7 4 2000 268-275
27. K.R. Aigner S. Gailhofer Celic axis infusion (MMC, CDDP, 5-FU) and aortic stop-flow infusion vs abdominal hypoxic perfusion (MMC) in UICC stage III/IV pancreatic cancer-48 patients Reg Cancer Treat 6 3 1993
28. K.R. Aigner Regional chemotherapy-editorial review article Reg Cancer Treat 2 1994 55-66
29. K.R. Aigner Pelvic stopflow infusion and hypoxic pelvic perfusion-techniques and pharmacokinetics Reg Cancer Treat 1995 6
30. B.A. Teicher J.S. Lazo A.C. Sartorelli Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells Cancer Res 41 1 1981 73-81
31. P. Vaupel F. Kallinowski P. Okunieff Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review Cancer Res 49 23 1989 6449-6465
32. J.F. Thompson M. Liu L.D. Watson D.M. Sheldon M.S. Stephan D.W. Storey et al. A percutaneous aortic stop-flow infusion technique for regional cytotoxic therapy of the abdomen and pelvis Reg Cancer Treat 7 1994 202-207
33. P.S. Turk J.F. Belliveau J.W. Darnowski M.C. Weinberg L. Leenen H.J. Wanebo Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique Arch Surg 128 5 1993 533-538
34. A.M. Averbach O.A. Stuart T.A. Sugarbaker A.D. Stephens V. Fernandez-Trigo F. Shamsa et al. Pharmacokinetic studies of intraaortic stop-flow infusion with 14C-labeled mitomycin C J Surg Res 59 3 1995 415-419
35. M.G. van IJken B. van Etten G. Guetens T.L. ten Hagen J. Jeekel E.A. de Bruijn et al. Balloon catheter hypoxic abdominal perfusion with mitomycin C and melphalan for locally advanced pancreatic cancer: A phase I-II trial Eur J Surg Oncol 30 6 2004 671-680
36. M.G. van IJken E.A. de Bruijn T.L. ten Hagen G. de Boeck C.H. van Eijck A.M. Eggermont Balloon catheter hypoxic abdominal and pelvic perfusion with tumour necrosis factor-alpha, melphalan and mitomycin C: A pharmacokinetic study in pigs Eur J Surg Oncol 30 6 2004 699-707
37. M. Lorenz H. Petrowsky S. Heinrich G. Janshon E. Staib-Sebler Y. Poloczek et al. Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer Eur J Surg Oncol 24 6 1998 542-547
38. A.M. Averbach O.A. Stuart T.A. Sugarbaker A.D. Stephens V. Fernandez-Trigo F. Shamsa et al. Intraaortic stop-flow infusion: pharmacokinetic feasibility study of regional chemotherapy for unresectable gastrointestinal cancers Ann Surg Oncol 2 4 1995 325-331
39. K.R. Aigner Aortic stopflow infusion (ASI) and hypoxic abdominal perfusion (HAP) for disseminated bulky peritoneal carcinomatosis-rationale and technique Reg Cancer Treat 6 3 1993
40. K.R. Aigner K. Kaevel Pelvic stopflow perfusion and hypoxic pelvic perfusion with MMC and melphalan for recurrent rectal cancer Reg Cancer Treat 7 1994 6-11
41. H.J. Wanebo J.F. Belliveau A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion Cancer Chemother Pharmacol 43 5 1999 427-434
42. H.J. Wanebo J. Belliveau G. Begossi A. Levy Isolated chemotherapeutic perfusion of the pelvis for advanced rectal cancer Colorectal Dis 5 5 2003 508-514
43. A.M. Averbach T.A. Sugarbaker Advanced gastric cancer: Review of regional chemotherapy trials and treatment strategies using stop-flow infusion Reg Cancer Treat 8 1995 67-76
44. G. Fiorentini D. Poddie S. Ricci Intra-aorticstop-flow infusion with hypoxic abdominal perfusion in UICC stage III/IV pancreatic carcinoma: report of a phase II study Reg Cancer Treat 9 1996 88-91
45. M. Lorenz S. Heinrich E. Staib-Sebler C.H. Kohne J. Wils B. Nordlinger et al. Regional chemotherapy in the treatment of advanced pancreatic cancer-is it relevant? Eur J Cancer 36 8 2000 957-965
46. T. Gebauer K. Ridwelski J. Fahlke H. Lippet Locoregional and systemic therapy in advanced pancreatic carcinoma Arch Chir Suppl 2 1998 1344-1347
47. V.S. Guadigni M. Lorenz Letter to the editor Eur J Surg Oncol 25 1999 339-340
48. C.J. McGinn T.S. Lawrence M.M. Zalupski On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer Cancer 95 4 Suppl 2002 933-940
49. G.P. van der Schelling J. Jeekel Palliative chemotherapy and radiotherapy for pancreatic cancer: Is it worthwhile? World J Surg 23 9 1999 950-953
50. H.A. Burris 3rd M.J. Moore J. Andersen M.R. Green M.L. Rothenberg M.R. Modiano et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 6 1997 2403-2413
51. Van IJken MG, Van Etten B, Guetens G, De Bruijn EA, Ten Hagen TLM, Wiggers Th, et al. Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: A phase I-II trial. Eur J Surg Oncol. In press.
52. T. Wiggers M.R. de Vries B. Veeze-Kuypers Surgery for local recurrence of rectal carcinoma Dis Colon Rectum 39 3 1996 323-328
53. E. Chrysos J. Tsiaoussis K. Alexandra H. Athanasakis D. Tsetis C. Varveris et al. Treatment of unresectable malignant abdominal, pelvic and thoracic tumors using abdominal pelvic and thoracic stop-flow chemotherapy Anticancer Res 21 5 2001 3669-3675
54. S. Guadagni M. Santinami R. Patuzzo P.L. Pilati D. Miotto M. Deraco et al. Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: A pilot study Melanoma Res 13 1 2003 51-58
55. M. Delaney M. Stancu G. Begossi G.J. Elfenbein H.J. Wanebo Neoadjuvant therapy with high dose chemotherapy via isolated pelvic intra-abdominal perfusion with bone marrow stem cell support for advanced endometrial cancer Med Health R I 86 8 2003 252-255
56. H. Muller R. Hilger Curative and palliative aspects of regional chemotherapy in combination with surgery Support Care Cancer 11 1 2003 1-10
57. J. Hofland R. Tenbrinck I.M.G. Van C.H. van Eijck A.M. Eggermont W. Erdmann Cardiovascular effects of simultaneous occlusion of the inferior vena cava and aorta in patients treated with hypoxic abdominal perfusion for chemotherapy Br J Anaesth 88 2 2002 193-198
58. E.S. Klein G.Y. Ben-Ari M.Z. Papa R. Adar A. Bass Vascular complications of total abdominal perfusion and aortic stop-flow infusion J Surg Oncol 61 1 1996 17-19
59. M.G. van IJken E.A. de Bruijn G. de Boeck T.L. ten Hagen J.R. van der Sijp A.M. Eggermont Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: A pharmacokinetic study in pigs Ann Surg 228 6 1998 763-770
60. S. Hill W.J. Fawcett J. Sheldon N. Soni T. Williams J.M. Thomas Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion Br J Surg 80 8 1993 995-997
61. N. Renard P.T. Nooijen L. Schalkwijk R.M. De Waal A.M. Eggermont D. Lienard et al. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha J Pathol 176 3 1995 279-287
62. M. Kornmann U. Butzer J. Blatter H.G. Beger K.H. Link Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer Eur J Surg Oncol 26 6 2000 583-587
63. J.P. Neoptolemos D. Cunningham H. Friess C. Bassi D.D. Stocken D.M. Tait et al. Adjuvant therapy in pancreatic cancer: Historical and current perspectives Ann Oncol 14 5 2003 675-692
64. A.E. Chang P.D. Schneider P.H. Sugarbaker C. Simpson M. Culnane S.M. Steinberg A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases Ann Surg 206 6 1987 685-693
65. M.A. Choti G.B. Bulkley Management of hepatic metastases Liver Transpl Surg 5 1 1999 65-80
66. S.S. Yoon K.K. Tanabe Surgical treatment and other regional treatments for colorectal cancer liver metastases Oncologist 4 3 1999 197-208
67. N. Kemeny F. Fata Hepatic-arterial chemotherapy Lancet Oncol 2 7 2001 418-428
68. G.M. Mavligit A.A. Zukiwski C. Charnsangavej C.H. Carrasco S. Wallace J.U. Gutterman Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases Cancer 69 2 1992 557-561
69. A. Marinelli C.J. van de Velde P.J. Kuppen H.C. Franken J.H. Souverijn A.M. Eggermont A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats Br J Cancer 62 6 1990 891-896
70. A. Marinelli J.H. van Dierendonck G.M. van Brakel H. Irth P.J. Kuppen U.R. Tjaden et al. Increasing the effective concentration of melphalan in experimental rat liver tumours: Comparison of isolated liver perfusion and hepatic artery infusion Br J Cancer 64 6 1991 1069-1075
71. D. Christoforidis O. Martinet F.J. Lejeune F. Mosimann Isolated liver perfusion for non-resectable liver tumours: A review Eur J Surg Oncol 28 8 2002 875-890
72. A. Marinelli F.R. Dijkstra J.H. van Dierendonck P.J. Kuppen C.J. Cornelisse C.J. van de Velde Effectiveness of isolated liver perfusion with mitomycin C in the treatment of liver tumours of rat colorectal cancer Br J Cancer 64 1 1991 74-78
73. I.H. Borel Rinkes M.R. de Vries A.M. Jonker T.J. Swaak C.E. Hack P.T. Nooyen et al. Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan Br J Cancer 75 10 1997 1447-1453
74. A.L. Vahrmeijer J.H. van Dierendonck H.J. Keizer J.H. Beijnen R.A. Tollenaar M.E. Pijl et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: A phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver Br J Cancer 82 9 2000 1539-1546
75. J. Rothbarth M.E. Pijl A.L. Vahrmeijer H.H. Hartgrink F.G. Tijl P.J. Kuppen et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver Br J Surg 90 11 2003 1391-1397
76. H.R. Alexander Jr D.L. Bartlett S.K. Libutti Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver Oncologist 5 5 2000 416-424
77. A. Marinelli L.M. de Brauw H. Beerman H.J. Keizer J.H. van Bockel U.R. Tjaden et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver Jpn J Clin Oncol 26 5 1996 341-350
78. M.R. de Vries I.H. Rinkes C.J. van de Velde T. Wiggers R.A. Tollenaar P.J. Kuppen et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: Experimental studies in pigs and phase I data from humans Recent Results Cancer Res 147 1998 107-119
79. T.E. Lans D.L. Bartlett S.K. Libutti M.F. Gnant D.J. Liewehr D.J. Venzon et al. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion Clin Cancer Res 7 4 2001 784-790
80. D.L. Fraker H.R. Alexander A.K. Thom Use of tumor necrosis factor in isolated hepatic perfusion Circ Shock 44 1 1994 45-50
81. M.R. de Vries T.L. ten Hagen A.W. Marinelli A.M. Eggermont Tumor necrosis factor and isolated hepatic perfusion: From preclinical tumor models to clinical studies Anticancer Res 23 2C 2003 1811-1823
82. E. Savier D. Azoulay E. Huguet F. Lokiec M. Gil-Delgado H. Bismuth Percutaneous isolated hepatic perfusion for chemotherapy: A phase 1 study Arch Surg 138 3 2003 325-332
83. A.M. Eggermont I.M.G. Van B. van Etten J.R. van der Sijp T.L. ten Hagen T. Wiggers et al. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: From laboratory to the clinic towards a percutaneous procedure Hepatogastroenterology 47 33 2000 776-781
84. Y. Ku M. Tominaga T. Iwasaki T. Fukumoto S. Muramatsu N. Kusunoki et al. Efficacy of repeated percutaneous isolated liver chemoperfusion in local control of unresectable hepatocellular carcinoma Hepatogastroenterology 45 24 1998 1961-1965
85. van Etten B, Brunstein F, van IJken MGA, Marinelli AWKS, Verhoef C, van der Sijp JRM, et al. Isolated hypoxic hepatic perfusion (IHHP) with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques. a phase I-II study. Am Surg Oncol 2004;11(6):598-605
86. J. Rothbarth M.E. Pijl R.A. Tollenaar F. Tijl G. Ivancev G.J. Mulder et al. An experimental minimally invasive perfusion technique for the treatment of liver metastases Eur J Surg Oncol 29 9 2003 757-763
87. Brunstein F, Hoving S, Seynhaeve ALB, Van Tiel ST, De Boeck G, De Bruijn EA, et al. Synergistic anti-tumor activity of histamine plus melphalan in the isolated limb perfusion (ILP)-preclinical studies. J Natl Cancer Inst 2004;96(21):1603-10.
88. Brunstein F, Seynhaeve ALB, Van Tiel ST, De Boeck G, De Bruijn EA, Eggermont AMM, et al. Synergistic antitumor activity of histamine plus melphalan in the isolated hepatic perfusion (IHP) without increased liver toxicity. Submitted for publication.